Tuesday October 17th 2017

Ipsen: Dysport Phase IIa clinical trial effective in treatment of NDO

Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY) today announced positive results from its phase IIa clinical trial assessing Dysport in the treatment of Neurogenic Detrusor Overactivity (NDO) in patients with urinary incontinence not adequately managed by anticholinergics.

Continue at source: 

Ipsen: Dysport Phase IIa clinical trial effective in treatment of NDO

Leave a Comment

More from category

Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS
Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS

Roche announced today that new data on OCREVUS ® (ocrelizumab) in people with relapsing and primary progressive forms [Read More]

All you need to know about dysesthesia
All you need to know about dysesthesia

Dysesthesia is a painful, itchy sensation, often associated with multiple sclerosis (MS). Learn more about the symptoms [Read More]

Medical News Today: All you need to know about dysesthesia
Medical News Today: All you need to know about dysesthesia

Dysesthesia is a painful, itchy sensation, often associated with multiple sclerosis (MS). Learn more about the symptoms [Read More]

MRI brain scans can reveal MS risk in children before clinical symptoms appear
MRI brain scans can reveal MS risk in children before clinical symptoms appear

By the time multiple sclerosis (MS) is diagnosed in children, it may be difficult to prevent the disabilities and [Read More]

Open Enrollment for Marketplace and Medicare Plans
Open Enrollment for Marketplace and Medicare Plans

/About-the-Society/News/Open-Enrollment-for-Marketplace-and-Medicare-Plans [Read More]